Thelansis

Camurati-Engelmann Disease (CED) Market Outlook Thelansis’s “Camurati-Engelmann Disease (CED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Camurati-Engelmann Disease (CED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest im...

Camurati-Engelmann Disease (CED) Market Outlook Thelansis’s “Camurati-Engelmann Disease (CED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Camurati-Engelmann Disease (CED) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Camurati-Engelmann Disease (CED) Overview Camurati-Engelmann Disease (CED) is a rare genetic condition characterized by excessive bony growth affecting the long bones, skull, spine, and pelvis. Excessive growth leads to clinical symptoms such as severe pain in the extremities, joint contractures, muscle weakness, and easy fatigability. The onset of the disease is variable, with an average onset of around 13 y...

 Camurati-Engelmann Disease (CED) is a rare genetic condition characterized by excessive bony growth affecting the long bones, skull, spine, and pelvis. Excessive growth leads to clinical symptoms such as severe pain in the extremities, joint contractures, muscle weakness, and easy fatigability. The onset of the disease is variable, with an average onset of around 13 years and almost always before 30 years of age. The symptoms can worsen with time and result in decreased muscle mass, joint contractures, and facial abnormalities such as frontal bossing and enlarged mandible. In some cases, the orbit involvement can lead to vision problems and hearing loss. Diagnosis of CED is based on clinical and radiographic findings and can be confirmed by genetic testing, which reveals mutations in the TGFB1 gene in over 90% of patients. Currently, there are no universally agreed-upon recommendations for treating CED, and the prognosis is poor, with a significant impact on quality of life due to...